Printer Friendly

Baxter to invest USD10m in Ontario plant.

M2 EQUITYBITES-November 6, 2014-Baxter to invest USD10m in Ontario plant


Baxter Corporation (NYSE:BAX), a company that develops, manufactures and markets products that save and sustain the lives of people with haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions, is investing USD10m to construct a new facility in Mississauga, Ontario, it was reported yesterday.

The facility will be used for the company's Centralized Intravenous Admixing Pharmacy Service (CIVA). The new Baxter CIVA Pharmacy Service is intended to expand the company's ability to meet the needs of Canadian hospitals, clinics and other care facilities for ready-to-administer intravenous admixtures, including chemotherapy, high alert medications and anti-infectives, allowing pharmacists to focus on more direct patient care and clinical activities.

The new facility will double the number of clean rooms available to support customised requirements for hazardous and non-hazardous IV admixing, and the firm aims to expand its workforce by around 25 positions over the next few years.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:1CONT
Date:Nov 6, 2014
Previous Article:Genworth MI Canada declares 11% higher regular dividend of USD0.39 per share and special dividend of USD0.43 per share for Q4 2014.
Next Article:Imprimis Pharmaceuticals signs distribution agreement with MD Distributor.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters